<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040350</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1151-9883</org_study_id>
    <nct_id>NCT02040350</nct_id>
  </id_info>
  <brief_title>Is the WHO Recommended Dose of Pralidoxime Effective in the Treatment of Organophosphorus Poisoning?</brief_title>
  <official_title>Study Effect of WHO Recommended Dose of Pralidoxime in the Treatment of Organophosphorus Poisoning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheri Kashmir Institute of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheri Kashmir Institute of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of Pralidoxime, a drug used for treatment of pesticide
      poisoning (Organophosphorous poisonings)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study was designed to critically analyze the role of pralidoxime in patients with
      moderate to severe poisoning by dividing them into two comparable groups in all aspects and
      using WHO recommended dose of pralidoxime (30mg/kg bolus I.V over 20 min followed by
      8mg/kg/hr continuous infusion). This dose and continuous infusion protocol is more likely to
      maintain adequate blood concentrations of pralidoxime throughout 24 hours and thus would
      avoid any failures in effectiveness of pralidoxime because of inconsistent blood levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mortality rate</measure>
    <time_frame>upto one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of ventilation</measure>
    <time_frame>upto one year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>duration of ICU stay</measure>
    <time_frame>upto one year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Deaths</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo was given to compare the effects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pralidoxime</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pralidoxime for treating organophosphorous poisoning patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pralidoxime</intervention_name>
    <description>Pralidoxime was compared to placebo to study the effects of the drug on mortatlity</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Pralidoxime</arm_group_label>
    <other_name>Oximes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        history of alleged organophosphorus intake age &gt; 14 years &lt; 60 years clinical signs and
        symptoms of organophosphorus poisoning.

        Exclusion Criteria:

        &lt; 14 years or &gt; 60 years of age known pregnancy pralidoxime administration at the
        transferring hospital carbamate poisoning any chronic illnesses

        â‰¥ 12 hour interval from time of poisoning to initiation of treatment pre-hospital cardiac
        or respiratory arrest.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Showkat Gurcoo, MD</last_name>
    <role>Study Director</role>
    <affiliation>SKIMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheri kashmir insititute of medical sciences</name>
      <address>
        <city>Srinagar</city>
        <state>Srinagar Kashmir</state>
        <zip>190006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008 Feb 16;371(9612):597-607. Review.</citation>
    <PMID>17706760</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <last_update_submitted>January 16, 2014</last_update_submitted>
  <last_update_submitted_qc>January 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheri Kashmir Institute of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Tariq Wani</investigator_full_name>
    <investigator_title>Registar</investigator_title>
  </responsible_party>
  <keyword>Pralidoxime, atropine, organophosphorous poisoning.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poisoning</mesh_term>
    <mesh_term>Organophosphate Poisoning</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pralidoxime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

